Ellipses In-Licenses First-in-Class B7H3 Antibody Drug Conjugate From China

Contributed by: Business Wire

Logo

Tags

Oncology

Health

FDA

Research

Science

Biotechnology

More Like This

PR Newswire associated0

Ellipses' next generation selective RET inhibitor EP0031/A400 cleared to start Phase 2

Ellipses EP0031/A400 granted Orphan Drug Designation from the US Food and Drug Administration

PR Newswire associated0

Ellipses' next generation selective RET inhibitor EP0031/A400 granted Fast Track designation by US Food and Drug Administration

Oblique Therapeutics has entered a research collaboration agreement with Eli Lilly and Company to apply the AbiProt® technology to generate antibodies to a high-value target

Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings

Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference

Iksuda Therapeutics announces first patient successfully dosed in phase 1 trial evaluating IKS03 in advanced B cell non-Hodgkin lymphomas

Biocytogen Announces ADC Innovator Tubulis Has Signed Global Exclusive License Agreement for Single Antibody

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates